M&A / Deals Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic Pharmaceutical TechnologyThe funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress its bispecific ADC programmes to the clinic.M&A / DealsOncologyRead full story pharminent April 8, 2026 (Last updated: April 8, 2026) Pharmaceutical Technology The funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress its bispecific ADC programmes to the clinic. M&A / DealsOncologyRead full story Post navigation Previous: Activist investor renews its criticism of NovavaxNext: Medicare Advantage Insurers Will See Higher Payments as CMS Backs Off a Key Payment Update Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
